Postmarketing Safety Evaluation of New Molecular Entities: Final Report

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: Postmarketing Safety Evaluation of New Molecular Entities: Final Report

FDA/CDER/Division of Drug Information (DDI)

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA. 

The Office of Surveillance and Epidemiology and the Office of New Drugs in the Center for Drug Evaluation and Research (CDER) have completed the “NME Postmarketing Safety Evaluation Pilot Program” that began in January, 2007, and the final report is available.

In this pilot program, CDER undertook the systematic and collaborative review of the safety profiles of selected approved new molecular entities that have been marketed for varying lengths of time.  New molecular entities (NMEs) are drugs that include an active ingredient that has not previously been approved for marketing in the United States in any form.  The pilot program determined the value of such a systematic review.  As described in the final report, the pilot program also provided valuable information about the required resources and appropriate methods for conducting such a systematic evaluation.

For more information, please visit: New Molecular Entities


This is an automated message delivery system.  Replying to this message will not reach DDI staff.  If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm Monday - Friday.  You can also email us at druginfo@xxxxxxxxxxx.

For additional drug information, please visit the DDI Web page 

For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: FDA_Drug_Info 

Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.

This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420


[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux